Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 Diabetes

Abstract

This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.

1 . A method of preventing an increase in carotid intimal thickness in a patient diagnosed with a disease or condition selected from the group of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), early Type 2 diabetes, and Type 2 diabetes, comprising administering to said patient a therapeutically effective dosage of a long acting insulin. 
     
     
         2 . The method according to  claim 1  wherein the long acting insulin is insulin glargine. 
     
     
         3 . The method according to  claim 2  wherein the effective dosage is in the range of about 2 to about 150 IU per day. 
     
     
         4 . The method according to  claim 3  wherein the effective dosage is in the range of about 2 to about 80 IU per day. 
     
     
         5 . The method according to  claim 4  wherein the effective dosage is in the range of about 2 to about 40 IU per day.